Edition:
United States

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

363.50DKK
26 Apr 2017
Change (% chg)

kr.0.00 (+0.00%)
Prev Close
kr.363.50
Open
--
Day's High
--
Day's Low
--
Volume
82
Avg. Vol
205,627
52-wk High
kr.366.50
52-wk Low
kr.197.00

Latest Key Developments (Source: Significant Developments)

Valneva signs new EB66 commercial license with Bavarian Nordic
Tuesday, 18 Apr 2017 01:01am EDT 

April 18 (Reuters) - Valneva SE ::Announces signing of a new EB66 commercial license with Bavarian Nordic <<>>.Valneva's EB66 cell-line licensed to Bavarian Nordic for MVA-BN based product candidates.Valneva to support process development.The agreement grants Bavarian Nordic the rights to develop and commercialize multiple poxvirus-based vaccines on the EB66 cell-line.  Full Article

Bavarian Nordic FY EBIT rises to DKK 33.0 million
Wednesday, 15 Mar 2017 02:48am EDT 

Bavarian Nordic A/S : FY revenue 1.01 billion Danish crowns ($145 million) versus 1.02 billion crowns year ago . FY EBIT 33.0 million crowns versus 1.6 million crowns year ago . In 2017 sees revenue of 1.30 billion crowns .In 2017 sees EBIT of 350 million crowns.  Full Article

Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer
Friday, 10 Mar 2017 03:54am EST 

Bavarian Nordic A/S : Announces collaboration to evaluate CV301 and tecentriq in bladder cancer . Agreement with F. Hoffmann-La Roche Ltd (Roche) whereby Roche has agreed to supply their PD-L1 blocking antibody Tecentriq (atezolizumab) for a clinical study combining Bavarian Nordic's cancer vaccine, CV301, and Tecentriq in patients with urothelial carcinoma, or bladder cancer . Roche has committed to supplying Tecentriq to Bavarian Nordic during the phase 2 trial . Bavarian Nordic will be responsible for conducting clinical trial, and both companies will share data from trial .Bavarian Nordic continues to retain all commercial rights to CV301.  Full Article

Bavarian Nordic ups forecast for 2016 year-end cash preparedness
Tuesday, 3 Jan 2017 05:28am EST 

Bavarian Nordic A/S : Upgrades expectations for 2016 year-end cash preparedness to about 2.30 billion Danish crowns ($322.22 million) from about 1.90 billion crowns . Upgrade is primarily result of payments for IMVAMUNE deliveries, which were received earlier than expected and to minor extent increased USD exchange rate as well as deferred investments .Maintains its expectations for 2016 revenues of about 1.00 billion crowns and break-even result before interest and tax.  Full Article

Bavarian Nordic names Christopher Heery Chief Medical Officer
Wednesday, 28 Sep 2016 07:00am EDT 

Bavarian Nordic A/S : Appoints Christopher Heery, M.D., as Chief Medical Officer .Most recently, Dr. Heery was Director of Clinical Trials Group of Laboratory of Tumor Immunology and Biology at National Cancer Institute.  Full Article

Bavarian Nordic Q2 EBIT swings to loss DKK 54.0 million
Wednesday, 17 Aug 2016 01:53am EDT 

Bavarian Nordic A/S : H1 revenue 139 million Danish crowns ($21 million) versus 624 million crowns year ago . Q2 revenue 116.6 million crowns versus 389.1 million crowns year ago . Q2 EBIT loss 54.0 million crowns versus profit 125.0 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

Bavarian Nordic: Expansion of IMVAMUNE orders from Canada
Wednesday, 15 Jun 2016 09:04am EDT 

Bavarian Nordic A/S : Announces expansion of IMVAMUNE orders from Canadian government . Canadian government exercised option for supply of 171,000 doses of IMVAMUNE smallpox vaccine to national stockpile at total value of $7.7 million .Says contents of this announcement do not affect company's expectations for financial results for 2016.  Full Article

Bavarian Nordic Q1 EBIT loss increases to DKK 153 million
Friday, 13 May 2016 01:47am EDT 

Bavarian Nordic A/S : Q1 revenue 23 million Danish crowns ($3.52 million) versus 235 million crowns year ago . Q1 EBIT loss 153 million crowns versus loss 40 million crowns year ago .Maintains its financial expectations for 2016.  Full Article

Bavarian Nordic A/S: Positive data for Ebola vaccine regimen
Monday, 18 Apr 2016 06:00pm EDT 

Bavarian Nordic A/S:Results of Phase 1 study of a preventive Ebola vaccine regimen suggest that regimen was well-tolerated by healthy volunteers and did not result in any vaccine-related serious adverse events.Study tested vaccine regimen containing two components, of which one was based on MVA-BN technology from Bavarian Nordic.Confirmed data from a Phase 1 study of a preventive Ebola vaccine regimen have been published in The Journal of the American Medical Association.  Full Article

Bavarian Nordic completes a private placement at market price
Monday, 18 Apr 2016 02:03am EDT 

Bavarian Nordic A/S:Completes a private placement at market price.Says subscription price is 240 Danish crowns per share.Raises gross proceeds in private placement of about 665 million crowns.Raises expectations to FY 2016 year-end cash preparedness to level of 1.90 billion crowns from 1.30 billion crowns.  Full Article

More From Around the Web

BRIEF-Valneva signs new EB66 commercial license with Bavarian Nordic

* Announces signing of a new EB66 commercial license with Bavarian Nordic